← back to search

Christopher Schroeder

University of Tübingen · DE
Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Genetic factors in colorectal cancer, and Genomics and Rare Diseases.
h-index
25
citations
2,346
works
107
NIH funding
primary concept
email

Recent publications

Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition
Nature Communications 2024cited by 18position: firstdoi
Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse
British Journal of Cancer 2023cited by 39position: middledoi
Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients
npj Precision Oncology 2023cited by 32position: middledoi
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
Neuro-Oncology Advances 2023cited by 18position: middledoi
Biallelic MAD2L1BP (p31comet) mutation is associated with mosaic aneuploidy and juvenile granulosa cell tumors
JCI Insight 2023cited by 7position: middledoi
The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients
Journal of Laboratory Medicine 2022cited by 3position: middledoi
Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany
Seminars in Cancer Biology 2021cited by 38position: middledoi
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma
npj Precision Oncology 2021cited by 30position: middledoi
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours
Nature Communications 2020cited by 130position: middledoi
Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy
Radiotherapy and Oncology 2020cited by 57position: middledoi
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options
JCO Precision Oncology 2020cited by 21position: middledoi
PET/MRI and genetic intrapatient heterogeneity in head and neck cancers
Strahlentherapie und Onkologie 2020cited by 10position: middledoi
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
Genome Medicine 2019cited by 178position: middledoi
A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer
Frontiers in Immunology 2019cited by 42position: middledoi
Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D
Strahlentherapie und Onkologie 2019cited by 38position: middledoi
Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy
Radiotherapy and Oncology 2018cited by 25position: lastdoi
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications
BMC Medical Genetics 2018cited by 12position: lastdoi
Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology
American Journal of Medical Genetics Part A 2017cited by 277position: middledoi
Organ preservation in rectal cancer – Challenges and future strategies
Clinical and Translational Radiation Oncology 2017cited by 36position: middledoi
Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient
Journal of Hepatology 2016cited by 87position: middledoi
PRRT2 Mutations are the major cause of benign familial infantile seizures
Human Mutation 2012cited by 105position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Olaf Rieß · University Children's Hospital Tübingen7 papers (2018–2023)Franz J. Hilke · Humboldt-Universität zu Berlin6 papers (2018–2020)Stephan Ossowski · German Cancer Research Center6 papers (2018–2024)Daniel Zips · Auguste-Viktoria-Klinik6 papers (2017–2020)Jakob Admard · University of Tübingen4 papers (2020–2024)Stefan Welz · Marienhospital Stuttgart4 papers (2018–2020)Sergios Gatidis · Artificial Intelligence in Medicine (Canada)3 papers (2020–2024)Dominik Nann · University of Tübingen3 papers (2020–2021)Kerstin Zwirner · University of Tübingen3 papers (2017–2019)Konstantin Nikolaou · German Cancer Research Center3 papers (2020–2021)Irina Bonzheim · STZ eyetrial3 papers (2018–2024)Cihan Gani · German Cancer Research Center3 papers (2017–2019)Nisar P. Malek · STZ eyetrial2 papers (2020–2021)Martin Schulze · University of Tübingen2 papers (2020–2021)Daniela Thorwarth · German Cancer Research Center2 papers (2019–2020)Ingmar Königsrainer · University of Tübingen2 papers (2018–2019)Marius Horger · Universitätsklinikum Tübingen2 papers (2020–2021)Hans‐Georg Rammensee · University of Tübingen2 papers (2018–2019)Kerstin Clasen · University of Tübingen2 papers (2020–2020)Stefan Beckert · University of Tübingen2 papers (2018–2019)